Sanofi and Owkin deepen AI partnership with five-year K Pro license for drug development

Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative - Sanofi (NASDAQ:SNY)

The agreement also includes a five-year license for Owkin's AI Scientist platform, K Pro, marking the latest phase in a relationship that began in 2021. Partnership Builds On Existing AI Research Efforts The companies first teamed up through a 90 million euro strategic partnership centered on oncology target identification and patient subgroup analysis. The collaboration was later broadened to support drug positioning efforts within Sanofi's immunology pipeline. The newly announced initiative represents a deeper integration of AI into pharmaceutical research workflows. Under the agreement, Owkin will lead the end-to-end development of AI-driven biopharma agents built specifically for Sanofi. K Pro To Support Drug Development Decisions The AI agents will be deployed through K Pro, Owkin's AI Scientist platform. K Pro combines multimodal patient data with specialized biological AI systems to support activities across the early-stage discovery through clinical development. Sanofi Targets Faster And More Confident Decision-Making Owkin said the development of K Pro aligns with its broader goal of achieving Biological Artificial Superintelligence, a technology that could help the pharmaceutical industry tackle and potentially automate some of its most complex R&D challenges. The collaboration aims to enhance the discovery and development of new medicines, leveraging Anthropic's advanced AI capabilities to connect over 30,000 employees with critical institutional knowledge. The company broadened its multi-year collaboration with Tempus to enhance oncology research and development. SNY Stock Price Activity: Sanofi shares were up 1.33% at $44.97 during premarket trading on Friday, according to Benzinga Pro data. Image via Shutterstock Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Owkin And Sanofi Enter Multi-Year Collaboration To Co-Develop Next-Generation Biopharma Agents Backed By Five-Year License For K Pro

Owkin announced that it has entered into a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin?s AI Scientist. Owkin and Sanofi have collaborated since 2021 through a EUR 90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi?s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built for Sanofi. These AI agents will work like intelligent assistants, autonomously performing complex tasks in drug research and development. They will be deployed through K Pro, with the aim of complementing and reinforcing Sanofi?s existing agentic AI capabilities. K Pro combines multimodal patient data with specialized biological, agentic AI systems to support each stage of the pharmaceutical value chain, from early discovery through clinical development, while providing competitive intelligence, enabling faster, more informed, and more precise decisions. K Pro?s development is part of Owkin?s mission to achieve Biological Artificial Superintelligence to unlock new therapeutic discoveries beyond the limits of human cognition alone. Owkin believes this technology will enable the pharmaceutical industry to address, and ultimately automate, some of the most complex challenges in R&D.